Canbridge gains China rights to APG101

Apogenix GmbH (Heidelberg, Germany) granted Canbridge Life Sciences Ltd. (Beijing, China) exclusive rights to APG101 in China, Macao and Hong Kong to treat glioblastoma

Read the full 245 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE